Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of Intensive Urate Lowering With Combined Verinurad and Febuxostat on Albuminuria in Patients With Type 2 Diabetes: A Randomized Trial
Austin G. Stack, Nalina Dronamraju, Joanna Parkinson, et al.
American Journal of Kidney Diseases (2020) Vol. 77, Iss. 4, pp. 481-489
Open Access | Times Cited: 57

Showing 1-25 of 57 citing articles:

SGLT2 Inhibition and Uric Acid Excretion in Patients with Type 2 Diabetes and Normal Kidney Function
Danii L. S. Suijk, Michaël J.B. van Baar, Erik J.M. van Bommel, et al.
Clinical Journal of the American Society of Nephrology (2022) Vol. 17, Iss. 5, pp. 663-671
Open Access | Times Cited: 71
Comparative assessment of the effects of dotinurad and febuxostat on the renal function in chronic kidney disease patients with hyperuricemia
Tomoaki Takata, Sosuke Taniguchi, Yukari Mae, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 2
Impact of hyperuricemia on chronic kidney disease and atherosclerotic cardiovascular disease
Hitoshi Nishizawa, Norikazu Maeda, Iichiro Shimomura
Hypertension Research (2022) Vol. 45, Iss. 4, pp. 635-640
Closed Access | Times Cited: 62
Emerging Urate-Lowering Drugs and Pharmacologic Treatment Strategies for Gout: A Narrative Review
Robert Terkeltaub
Drugs (2023) Vol. 83, Iss. 16, pp. 1501-1521
Closed Access | Times Cited: 35
Gout therapeutics and drug delivery
Xiuju Peng, Xiaotong Li, Bing Xie, et al.
Journal of Controlled Release (2023) Vol. 362, pp. 728-754
Closed Access | Times Cited: 28
Advances in pharmacotherapies for hyperuricemia
Federica Piani, Davide Agnoletti, Claudio Borghi
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 6, pp. 737-745
Closed Access | Times Cited: 26
Combination Treatment with Verinurad and Allopurinol in CKD
Hiddo J.L. Heerspink, Austin G. Stack, Robert Terkeltaub, et al.
Journal of the American Society of Nephrology (2024) Vol. 35, Iss. 5, pp. 594-606
Closed Access | Times Cited: 12
Hyperuricemia and Progression of Chronic Kidney Disease: A Review from Physiology and Pathogenesis to the Role of Urate-Lowering Therapy
Tao Han Lee, Jia‐Jin Chen, Chao‐Yi Wu, et al.
Diagnostics (2021) Vol. 11, Iss. 9, pp. 1674-1674
Open Access | Times Cited: 42
Review of Urate-Lowering Therapeutics: From the Past to the Future
Christopher Jenkins, Jennifer H. Hwang, Jeffrey B. Kopp, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 36
Effect of uric acid reduction on chronic kidney disease. Systematic review and meta-analysis
Alfredo G. Casanova, Ana I. Morales, Laura Vicente-Vicente, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 7
Inhibition of Interleukin-33 to Reduce Glomerular Endothelial Inflammation in Diabetic Kidney Disease
Alexis Hofherr, Elena Liarte Marin, Barbara Musiał, et al.
Kidney International Reports (2024) Vol. 9, Iss. 6, pp. 1876-1891
Open Access | Times Cited: 6
Exploring barriers of health literacy on non-communicable disease prevention and care among patients in north wollo zone public hospitals; Northeast, Ethiopia, 2023: application of socio-ecological model
Eneyew Talie Fenta, Atitegeb Abera Kidie, Misganaw Guadie Tiruneh, et al.
BMC Public Health (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 6
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
Kaitlin J. Mayne, Rebecca J. Sardell, Natalie Staplin, et al.
Nephrology Dialysis Transplantation (2024)
Closed Access | Times Cited: 6
Can we cure diabetic kidney disease? Present and future perspectives from a nephrologist's point of view
Murilo Guedes, Roberto Pecoits–Filho
Journal of Internal Medicine (2021) Vol. 291, Iss. 2, pp. 165-180
Open Access | Times Cited: 32
Serum uric acid levels and diabetic kidney disease in patients with type 2 diabetes mellitus: A dose-response meta-analysis
Pan Ji, Jieyun Zhu, Jihua Feng, et al.
Primary care diabetes (2022) Vol. 16, Iss. 3, pp. 457-465
Closed Access | Times Cited: 22
Past, present and future of xanthine oxidase inhibitors: design strategies, structural and pharmacological insights, patents and clinical trials
Atamjit Singh, Karanvir Singh, Aman Sharma, et al.
RSC Medicinal Chemistry (2023) Vol. 14, Iss. 11, pp. 2155-2191
Closed Access | Times Cited: 11
Association between urinary uric acid excretion and kidney outcome in patients with CKD
Yuta Asahina, Yusuke Sakaguchi, Tatsufumi Oka, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 4
The effect of glucagon‐like peptide‐1 receptor agonists on serum uric acid concentration: A systematic review and meta‐analysis
Sara Najafi, Milad Bahrami, Alexandra E. Butler, et al.
British Journal of Clinical Pharmacology (2022) Vol. 88, Iss. 8, pp. 3627-3637
Open Access | Times Cited: 18
Hyperuricemia-induced complications: dysfunctional macrophages serve as a potential bridge
Wenyi Gu, Jiajing Zhao, Yu Xu
Frontiers in Immunology (2025) Vol. 16
Open Access
Changes in Uric Acid Levels and Effects on Renal Function After Switching From Febuxostat to Dotinurad in Patients With Chronic Kidney Disease: A Retrospective Study
Akira Mima, Keishi Matsumoto, Takeo Matsuki, et al.
Cureus (2025)
Open Access
Xanthine oxidase inhibitor urate-lowering therapy titration to target decreases serum free fatty acids in gout and suppresses lipolysis by adipocytes
Mónica Gumá, Benyamin Dadpey, Roxana Coras, et al.
Arthritis Research & Therapy (2022) Vol. 24, Iss. 1
Open Access | Times Cited: 15
Pipeline Therapies for Gout
Kevin Yip, Genna Braverman, Linda Yue, et al.
Current Rheumatology Reports (2023) Vol. 26, Iss. 3, pp. 69-80
Closed Access | Times Cited: 8
Multicenter randomized controlled trial of intensive uric acid lowering therapy for CKD patients with hyperuricemia: TARGET-UA
Tetsuya Yamamoto, Masato Kasahara, Kenji Ueshima, et al.
Clinical and Experimental Nephrology (2024) Vol. 28, Iss. 8, pp. 764-772
Open Access | Times Cited: 3
Virtual screening and activity evaluation of human uric acid transporter 1 (hURAT1) inhibitors
Yacong Yang, Yu Hu, Fengli Yao, et al.
RSC Advances (2023) Vol. 13, Iss. 6, pp. 3474-3486
Open Access | Times Cited: 7
Efficacy of dotinurad in patients with severe renal dysfunction
Osamu Kurihara, Takehisa Yamada, Katsuhito Kato, et al.
Clinical and Experimental Nephrology (2023) Vol. 28, Iss. 3, pp. 208-216
Closed Access | Times Cited: 7
Page 1 - Next Page

Scroll to top